Drug intelligence / Profile preview

TRK-880

Development stage: Preclinical
Lead developer: Toray Industries

Overview

TRK-880 is a novel anti-cancer therapeutic candidate discovered by Systems Oncology and out-licensed to Toray Industries for development and commercialization, primarily in Japan and Asia. The drug was identified using Systems Oncology's AI-driven discovery platform, which translates complex cancer biology insights into drug development programs. While specific details regarding its molecular target and modality remain proprietary, TRK-880 is projected to have broad efficacy across multiple oncology indications. The collaboration combines Systems Oncology's discovery and biology insights with Toray's development and commercialization capabilities.

Beyond the preview

Go deeper on TRK-880.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRK-880.

Explore the full profile